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Objectives: To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced ﬁrst-
line dose of sunitinib or pazopanib compared to those who continue at the standard dose.
Patients and methods: All the patients treated in 11 oncological centers in Italy for mRCC who started ﬁrst-line treatment with sunitinib
or pazopanib at the standard dose. Descriptive statistical tests were used to highlight differences among groups. Survival was estimated by
the Kaplan-Meier method and compared across the groups using log-rank tests, the Cox proportional hazards model adjusted for statistically
signiﬁcant variables was also done.
Results: A total of 591 patients were included in the study. Of these, 45.7% received a reduced dose of sunitinib or pazopanib after a median
treatment time of 3.6 months at the standard dose. The median overall survival in the patients who continued to receive the standard dose was 24.0
months compared to 49.4 months for those who received a reduced dose (hazard ratio ¼ 1.80; 95% CI: 1.42–2.29; Po 0.001).
Only 45% of the patients received second-line therapy: 42.5% had an mTOR and 54.1% a tyrosine kinase inhibitor. Second-line overall survival
was 19.8 and 11.8 months, respectively, in the patients who received, or did not, a reduced dose during ﬁrst-line therapy (P ¼ 0.007).
Conclusions: Toxicity-related dose reduction is a common event in mRCC patients who have started ﬁrst-line therapy with either sunitinib or
pazopanib. This is positively related to the outcomes of both ﬁrst- and second-line therapy. r 2017 Elsevier Inc. All rights reserved.
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In recent years, many drugs targeting the vascular endothe-
lial growth factor/vascular endothelial growth factor receptor
(VEGFR) axis have been approved for the treatment of
metastatic renal cell carcinoma (mRCC) based on advantages
in clinical outcomes demonstrated in large phase III clinical
trials. Among these drugs, sunitinib and pazopanib are both
considered to be standard ﬁrst-line treatment and were recently
compared in a noninferiority phase III trial that reported similar
outcomes with a different toxicity proﬁle [1,2]. Despite an
increased understanding of drug-related toxicity proﬁles and the
improved expertise of the clinicians involved in the manage-
ment of mRCC patients, both drugs are characterized by a
variety of adverse events that lead to dose interruptions or
reductions in more than 40% of cases [1].
In general, treatment-related toxicity negatively affects a
patient's quality of life, although suboptimal tolerability
leading to dose reduction has long been considered to
undermine the beneﬁts of therapy. To improve patient
outcomes, early identiﬁcation, prevention, and the treatment
of toxicities are crucial for maximizing the efﬁcacy of
therapy. Recently, a model has also been proposed for
predicting toxicity-related treatment discontinuation in
patients with mRCC receiving VEGFR inhibitors. In this
model, age, the glomerular ﬁltration rate, the number of
metastatic sites, and baseline sodium levels were found to
be independent risk factors for toxicity-related treatment
discontinuation [3].
Despite this, the outcomes of patients who receive a
reduced dose due to treatment-related adverse events have
been investigated less. Herein, we aim to describe the
effects of dose reductions as a consequence of treatment-
related toxicity on the outcomes of patients with mRCC
treated with standard ﬁrst-line sunitinib or pazopanib.2. Materials and methods
2.1. Patients
Patients with mRCC treated in 11 oncological centers in
Italy with ﬁrst-line sunitinib or pazopanib were included in
the study. The patients were required to have a histological
diagnosis of clear cell RCC and to have started ﬁrst-line
treatment at the standard doses (i.e., sunitinib ¼ 50 mg
daily with a 4/2 schedule; pazopanib ¼ 800 mg daily
continuously). Adequate information about the baseline
Eastern Cooperative Oncology Group performance status,
the extent of the disease, and the biochemical parameters
(i.e., hemoglobin, platelets, neutrophils, and serum calcium)
was also required. The patients should also have been given
information about dose reductions, as well as the date and
level of dose they were receiving and the main reason for
any changes. Toxicity was classiﬁed according to the
Common Terminology Criteria for Adverse Events(CTCAE) v3.0 [4]. A prognostic group at baseline was
evaluated for each patient using the International mRCC
Database Consortium (IMDC) criteria [5]. Data on the type
(mTOR vs. tyrosine kinase [TK] inhibitors) and length of
second-line therapy were also collected.
The patients were divided into 2 groups based on whether
they had experienced a dose reduction or not during ﬁrst-line
treatment. Baseline characteristics and outcomes were analyzed
separately. The patients who received reduced-dose treatment
were also classiﬁed based on the level of dose: ﬁrst (i.e.,
sunitinib ¼ 37.5 mg; pazopanib ¼ 600 mg) or second level
(i.e., sunitinib ¼ 25 mg; pazopanib ¼ 400 mg).
2.2. Statistics
Baseline values were expressed as the median and
interquartile range. The baseline was deﬁned as the start
date of treatment with sunitinib or pazopanib. Progression-
free survival (PFS) was evaluated from the start of ﬁrst- or
second-line treatment to the progression of the disease or
death. The patients were assessed for progression according
to the Agenzia Italiana del Farmaco (AIFA) Italian guide-
lines every 12 weeks, with progression evaluated by
RECIST v. 1.0. Overall survival (OS) was evaluated from
the baseline (OS1) or from the start of second-line therapy
(OS2) to death. All the survival rates were estimated using
the Kaplan-Meier method and compared across groups
using the log-rank test. Survival rates were also adjusted
for the IMDC prognostic classiﬁcation. A landmark analysis
was conducted to estimate PFS to avoid both selection bias
and the inclusion of patients with negative prognostic
features and, consequently, a shorter PFS (o4 mo).
A chi square or t-test was used to compare groups when
appropriate. The association of dose reduction as a con-
tinuous variable with OS or PFS was evaluated using the
Cox proportional hazards model, and the values were
adjusted for the IMDC criteria, age, sex, and whether or
not a nephrectomy had been performed. All the variables
were considered to be signiﬁcant at the level of Po 0.05.
The PASW software (Predictive Analytics SoftWare; v 21;
IBM SPSS) was used for the analysis. The approval of the
Ethics Committee was required and obtained for this study.3. Results
A total of 591 patients, treated from 2006 to 2016, were
included in the analysis. Sunitinib was the ﬁrst-line treat-
ment in 76.5% of cases and pazopanib in the remaining
23.5%. The baseline characteristics for the entire population
are reported in Table 1. At the date of the analysis, after a
median follow-up of 36 months, 421 patients had
experienced disease progression and 281 had died. In the
overall group, the median OS was 33.8 months (95% CI:
29.0–38.6) and the median PFS was 13.4 months
(95% CI: 11.8–15.1).
Table 1
Baseline characteristics of the patients
Characteristics Patients First-line dose reduction χ2
N ¼ 591 No Yes P value
N ¼ 321 N ¼ 270
Median age 63.2 (IQR: 55.4–70.9) 61.4 (IQR: 52.6–69.5) 65.1 (IQR: 58.4–72.4) o0.001a
Male sex 70.7% 74.1 66.6 0.09
Nephrectomy 87.3% 83.5 91.9 0.002
Metastatic at diagnosis 43.1% 47.7 37.7 0.016
Performance status
ECOG ¼ 0 70.9% 68.8 73.3 0.2
ECOG ¼ 1 25.2% 26.2 24.1
ECOG ¼ 2 3.9% 5.0 2.6
Hbo LLN 35.5% 36.8 34.1 0.5
Corrected Ca4 ULN 6.1% 7.5 6.3 0.6
PLT4 ULN 8.8% 11.2 5.9 0.024
Neu4 ULN 12.0% 14.0 9.6 0.1
Sites of disease
Lung 61.8% 62.3 61.1 0.8
Nodes 48.4% 47.0 50.0 0.5
Bone 28.9% 32.4 24.8 0.04
Liver 17.6% 20.6 14.1 0.04
Local 14.5% 12.8 15.9 0.3
Pancreas 11.0% 8.4 14.1 0.03
Brain 7.3% 8.7 5.5 0.1
IMDC prognostic group
Good 28.6% 24.9 33.0 0.003
Intermediate 58.2% 57.9 58.5
Poor 13.2% 17.1 8.5
Type of therapy
Sunitinib 76.5% 77.3 75.6 0.6
Pazopanib 23.5% 22.7 24.4
Ca ¼ calcium; ECOG ¼ Eastern Cooperative Oncology Group; Hb ¼ hemoglobin; IMDC ¼ International MRCC Database Consortium; IQR ¼
interquartile range; LLN ¼ low limit of normal; Neu ¼ neutrophils; PLT ¼ platelets; ULN ¼ upper limit of normal.
at Test.
Fig. 1. Number of patients and cycle of dose reduction.
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after a median period of 3.6 months on the standard dose
(95% CI: 2.9–4.2). The median number of cycles received
before dose reduction was 3 for both drugs (Fig. 1). In the
patients treated with sunitinib, the dose was reduced to
37.5 mg and 25 mg daily for 4weeks in every 6 in 189
(44.5%) and 15 (3.3%) cases, respectively. In the patients
treated with pazopanib, the dose was reduced to 600 mg and
400 mg daily in 46 (33.1%) and 20 (14.4%) cases,
respectively.
Differences in the baseline characteristics between the
patients who did or did not receive a reduced treatment dose
are reported in Table 1. Those who required a dose
reduction were more commonly older, had more often
undergone a nephrectomy (91.9% vs. 83.5%), less fre-
quently had metastases at diagnosis (37.7% vs. 47.7%), and
more often had favorable prognostic features based on the
IMDC classiﬁcation (Table 1).
Table 2
Main reasons for dose reduction in 204 patients treated with sunitinib
Toxicity All G2 G3 G4
N % N % N % N %
Asthenia 33 16.2 16 7.8 17 8.3 – –
HF syndrome 34 16.7 13 6.4 21 10.3 – –
Diarrhea 17 8.3 6 2.9 11 5.4 – –
PLT decrease 24 11.8 4 2.0 20 9.8 – –
Mucositis 20 9.8 7 3.4 13 6.4 – –
Hypertension 11 5.4 4 2.0 7 3.4 – –
Low WBC/neu. 9 4.4 – – 9 4.4 – –
Hepatic toxicity 1 0.5 1 0.5 – – – –
Anemia 8 3.9 6 2.9 2 1 – –
Cardiac toxicity 5 2.5 1 0.5 4 2 – –
Creatinine increase 5 2.5 5 2.5 – – – –
Nausea 3 1.5 2 1 1 0.5 – –
Dysgeusia – – – – – – – –
Anorexia 2 1 1 0.5 1 0.5 – –
Other causes 31 15.2 12 5.9 17 8.3 2 1
G ¼ grade; HF ¼ hand-foot; neu. ¼ neutrophils; N ¼ number; PLT
¼ platelets; WBC ¼ white blood cells.
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population were asthenia (16.3%), hand-foot syndrome
(13.3%), diarrhea (13.0%), and falls in platelet numbers
(10.4%). Other reasons are reported separately for the patients
treated with sunitinib (Table 2) or pazopanib (Table 3).3.1. Outcomes of ﬁrst-line treatment
The unadjusted median PFS of the patients who con-
tinued at the standard treatment dose was 9.2 months (95%
CI: 7.0–11.3) compared to 18.1 months (95% CI: 15.6–
20.6) for those whose dose was reduced (hazard ratio [HR]Table 3
Main reasons for dose reduction in 66 patients treated with pazopanib
Toxicity All G2 G3 G4
N % N % N % N %
Asthenia 11 16.7 3 4.5 8 12.1 – –
HF syndrome 2 3.0 – – 2 3.0 – –
Diarrhea 18 27.3 12 18.2 6 9.1 – –
PLT decrease 3 4.5 1 1.5 2 3.0 – –
Mucositis 2 3.0 2 3.0 – – – –
Hypertension 3 4.5 – – 3 4.5 – –
Low WBC/neu. 2 3.0 1 1.5 1 1.5 – –
Hepatic toxicity 8 12.1 2 3.0 6 9.1 – –
Anemia – – – – – – – –
Cardiac toxicity 2 3.0 1 1.5 1 1.5 – –
Creatinine increase 1 1.5 – – 1 1.5 – –
Nausea 1 1.5 – – 1 1.5 – –
Disgeusia 4 6.1 – – 4 6.1 – –
Anorexia 2 3.0 2 3.0 – – –
Other causes 7 10.6 5 7.6 2 3.0 – –
G ¼ grade; HF ¼ hand-foot; neu. ¼ neutrophils; N ¼ number; PLT
¼ platelets; WBC ¼ white blood cells.¼ 1.74; 95% CI: 1.43–2.12; Po 0.001). This difference
was conﬁrmed in the sunitinib population (7.0 vs. 18.1 mo;
Po 0.001) and in the patients who had undergone a
nephrectomy (11.1 vs. 18.6; Po 0.001). Once again, when
the effect of dose reduction on PFS was adjusted for IMDC
class, age, sex, and nephrectomy at baseline, it remained
signiﬁcant (HR ¼ 0.60; 95% CI: 0.47–0.66; Po 0.001)
(Fig. 2A, Supplementary Tables 1 and 3).
The unadjusted median OS of the patients who continued
at the standard dose was 24.0 months (95% CI: 18.1–29.4)
compared to 49.4 months (95% CI: 40.0–58.9) for those
whose dose was reduced (HR = 0.60; 95% CI: 0.47–0.76;
Po 0.001). This difference was conﬁrmed in the sunitinib
population (20.7 vs. 49.3 mo, Po 0.001) and in the
patients who had undergone a nephrectomy (30.1 vs.
53.1, Po 0.001). When the effect of dose reduction on
OS was adjusted for the IMDC class, age, sex, and
nephrectomy at baseline, it remained signiﬁcant (HR =
0.60; 95% CI: 0.49–0.73; Po 0.001) (Fig. 2B,
Supplementary Tables 2 and 4). Further dose reductions
to the second level were found to be related to a longer OS
but not to a longer PFS (Supplementary Table 5).
This landmark analysis, which excluded 131 patients
who did not receive at least 4 months of therapy, conﬁrmed
better outcomes with respect to both OS (HR ¼ 0.69; 95%
CI: 0.52–0.92; P ¼ 0.013) and PFS (HR ¼ 0.76; 95% CI:
0.61–0.95; P ¼ 0.016) for those who received a reduced
dose, even if the results were adjusted for the IMDC
prognostic group.
3.2. Outcomes of second-line treatment
Among the 591 evaluable patients, only 266 (45%)
received second-line therapy. This consisted of TK inhib-
itors in 113 cases (42.5%) and mTOR inhibitors in the
remaining 144 (54.1%). The most frequent second-line
treatments used were everolimus (53.3%), axitinib
(21.4%), and sorafenib (16.2%). The unadjusted median
second-line PFS of the patients who did not receive a
reduced ﬁrst-line dose was 3.7 months (95% CI: 3.0–4.4)
compared to 5.7 months (95% CI: 4.4–7.1) for those who
did (P ¼ 0.006). The unadjusted median OS from the start
of second-line therapy for the patients who did not receive a
reduced ﬁrst-line dose was 11.8 months (95% CI: 9.4–14.3)
compared to 19.8 months (95% CI: 17.1–22.6) for those
who did (P ¼ 0.007).
In the patients treated with an mTOR inhibitor, 84 did
not receive a reduced ﬁrst-line dose and 60 had experienced
a previous dose reduction. The median PFS was 3.1 months
(95% CI: 2.4–3.8) for the ﬁrst group and 4.6 months (95%
CI: 2.5–6.6) for the second (P ¼ 0.007) (Fig. 3A). The
median OS was 11.4 months (95% CI: 8.8–14.0) for
the ﬁrst group and 19.6 months (95% CI: 14.9–24.3) for
the second (P ¼ 0.016) (Fig. 3B).
In the patients treated with a TK inhibitor, 54 did not
receive a reduced ﬁrst-line dose, whereas 59 had
Fig. 2. Median (A) progression-free survival and (B) overall survival adjusted for IMDC prognostic group and nephrectomy in patients who reduced, or did
not, initial treatment dose.
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was 5.3 months (95% CI: 3.8–6.7) for the ﬁrst group and
6.1 months (95% CI: 2.6–9.5) for the second (P ¼ 0.3)
(Fig. 3C). The median OS was 13.2 months (95% CI:
6.8–19.6) for the ﬁrst group and 21.4 months (95%
CI: 15.7–27.2) for the second (P ¼ 0.4) (Fig. 3D).4. Discussion
This study reports that dose reductions related to adverse
events during ﬁrst-line therapy with sunitinib or pazopanib
do not negatively affect the outcomes of mRCC patients.
Previous evidence in the literature suggests a direct corre-
lation between the dose intensity and the effectiveness of
the therapy in patients [6]. An earlier pharmacokinetic/
pharmacodynamics study investigated the relationships
between sunitinib exposure in patients with advanced solid
tumors and clinical outcomes, including in patients with
gastrointestinal stromal tumors and metastatic renal cell
carcinoma (mRCC). This particular study reported that the
steady-state area under the curve of sunitinib plus its active
metabolite was related to the time to tumor progression and
OS. It was also reported that the dose was linked to a
variety of investigated sunitinib side effects such as a rise in
blood pressure and a drop in neutrophil numbers [6]. A
prospective phase II study comparing 2 different sunitinib
schedules (e.g., standard vs. 37.5 mg/d continuously)
reported that the lower continued dose was clinically
inferior compared to the standard dose in terms of PFS
(7.1 vs. 9.9 months), with no improvement in safety. This
suggested the superiority of the high-dose start approach
[7]. More recently, an alternative sunitinib schedule
(2 weeks on therapy followed by 1 week off) reported alonger period of PFS and a better safety proﬁle in patients
experiencing dose-limiting toxicity, even if the same result
was not achieved when given as upfront treatment [8].
Taken together, this evidence suggests that the initial dose
of sunitinib should be 50 mg, with a classic schedule of 4
weeks on followed by 2 weeks off, because any reduction
of the initial dose is not supported by the same degree of
effectiveness or a better safety proﬁle.
In our study, we only included patients who started on a
standard dose of sunitinib or pazopanib, and we found better
outcomes for those receiving a reduced initial treatment dose
because of toxicity. As reported, most patients reduce their
treatment doses because of grade 2 toxicities. This is not
unusual, because long-lasting low grade toxicity can negatively
affect a patient's quality of life. The role of toxicity as a
predictive factor in mRCC has been reported in previous
studies. Meanwhile, a recent piece of work by our group
analyzed the role of cumulative toxicity in mRCC patients
treated with sunitinib or pazopanib [9,10]. Moreover, another
study reported a better outcome for patients who continued
treatment with personalized, reduced doses of sunitinib after
initial toxicity compared to those treated with standard doses.
Unfortunately, the population included in that study was largely
heterogeneous, as only 60% of patients were treated during
ﬁrst-line therapy and a large number had a non–clear cell
histology [11]. The results of our study are in accordance with
those of a recent pooled analysis of the prognostic role of dose
reduction in patients enrolled in 5 prospective trials involving
sunitinib. However, unlike those ﬁndings, we are also able to
conﬁrm our results: on the basis of a landmark analysis that
excluded the ﬁrst 4 months of therapy; and in patients treated
with pazopanib [12].
This data are in contrast to that of another article that
analyzed the correlation between dose intensity and outcomes in
Fig. 3. Median progression-free survival and overall survival in patients who received second-line (A and B) mTOR or (C and D) tyrosine kinase inhibitors.
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reported worse outcomes for patients with a lower dose
intensity. A possible reason for this ﬁnding is that about 20%
of these patients started with a lower dose of sunitinib [13].
De Velasco et al., who compared the different second-line
outcomes of patients who discontinued ﬁrst-line therapy
because of disease progression or toxicity, reported similar
data. Obviously, patients with progressive disease have worse
outcomes than those who experience toxicity independent of the
class of therapy used in second-line treatment [14].
Our study also reports that the increased PFS in patients
who received reduced doses is related to an increased OS,
even if the effects do not seem to inﬂuence the outcome of
second-line treatment. In these patients, we reported that the
previous dose reductions due to sunitinib- or pazopanib-
related toxicity did not affect the outcome of treatment witha second VEGFR inhibitor, but these data may be due to the
low number of patients included in the analysis. Meanwhile,
previous toxicity seems to occur in patients who are more
responsive to mTOR inhibitors. A possible explanation for
our results is that toxicity and dose reductions are the
epiphenomena of a tumor or patient phenotype, with
increased sensitivity to targeted agents.
There are some limitations to our research owing to its
retrospective nature. Data on patient comorbidities, con-
comitant medications, and attitudes to managing adverse
events, which may have provided more insight, were not
available. As the cases considered were treated from 2006
onwards, pazopanib and axitinib were not immediately
available in Italy. Lastly, no prospective evaluation of
progression was available, even though the AIFA registry
dictates timings for clinical and radiological evaluations in
R. Iacovelli et al. / Urologic Oncology: Seminars and Original Investigations 35 (2017) 541.e7–541.e13 541.e13patients treated with high-cost drugs. The strengths of our
study include the large cohort of unselected patients who
were homogeneous for the type and dose of treatment at the
start of therapy, and the analysis of several known factors
that have a prognostic value in mRCC.
5. Conclusion
Dose reductions related to an adverse event during ﬁrst-line
treatment with sunitinib or pazopanib seem to be a positive
prognostic factor. Our data need to be conﬁrmed by prospec-
tive evidence, but could help physicians to select patients with
a greater sensitivity to sunitinib or pazopanib for whom the
initial dose could be reduced after toxicity without affecting
survival and preserving a good quality of life.
Appendix A. Supplementary material
Supplementary data are available in the online version of
this article at http://dx.doi.org/10.1016/j.urolonc.2017.05.007.References
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